Sign in

    John Walden

    Managing Director and Senior Equity Analyst at Citizens JMP

    John Walden is a Managing Director and Senior Equity Analyst at Citizens JMP, specializing in coverage of software, internet, and technology companies. He is recognized for his analytical depth and has closely followed public businesses such as Amplitude, Braze, Couchbase, GitLab, MongoDB, and HashiCorp, consistently ranking among the top analysts for accuracy and investment returns. Walden began his professional career in the early 2000s, previously serving in analyst roles at Stifel Nicolaus and JMP Securities prior to the JMP merger with Citizens, and has been with Citizens JMP since 2022. He maintains active FINRA registration with Series 7, 63, 86, and 87 licenses, and is regularly cited in investor rankings for his successful calls and sharp sector insight.

    John Walden's questions to Crinetics Pharmaceuticals (CRNX) leadership

    John Walden's questions to Crinetics Pharmaceuticals (CRNX) leadership • Q2 2025

    Question

    An analyst on behalf of John Walden from Citizens JMP requested more color on the potential endpoints for the Cushing's disease trial and how they might differ for adamelin's mechanism versus other approved drugs.

    Answer

    Chief Endocrinologist Alan Krasner explained that the primary endpoint is typically normalization of 24-hour urine free cortisol (UFC). He highlighted that adamelin is uniquely situated due to the unprecedented rapidity of UFC normalization seen in trials so far, with patients achieving normalization in less than ten days. He expressed excitement to see if this consistent finding holds in larger, longer trials.

    Ask Fintool Equity Research AI